Iran’s pharmaceutical industry is grappling with a severe crisis marked by declining production, financial instability, and widespread drug shortages. A recent report reveals that the profitability of many pharmaceutical companies has plummeted by over 30%, with net profit margins falling below 25%. This downturn stems largely from government-imposed pricing policies amid high inflation and volatile exchange rates, which have placed these companies under immense financial strain.
The financial challenges extend beyond reduced profitability. Companies are facing escalating debts and liquidity issues, with debt-to-asset ratios climbing from 58% to 64%. This financial strain has forced both state-owned and private enterprises to seek bank loans to maintain operations. Notably, firms such as “Rouz Darou” and “Pakhsh Razi” have reported decreased production, raising concerns about potential shutdowns and further exacerbating drug shortages.
Impact on Workforce and Industry Efficiency
The crisis has also taken a toll on the industry’s workforce. Specialists are leaving due to payment delays and financial uncertainties, with some relocating operations to neighboring countries. For instance, “Sobhan Oncology” has reported mounting debts and an inability to meet financial obligations. Additionally, a major holding company with 14 trillion tomans in annual sales is reportedly struggling to pay employee salaries.
Experts suggest that semi-governmental companies transfer managerial shares to the private sector to better leverage existing capacities. They argue that income limitations in the public sector hinder talent acquisition and operational efficiency. Over the past decade, the market share of semi-governmental and state-owned pharmaceutical companies has halved, reflecting a trend toward inefficiency.
Tangible Effects on Drug Availability
The crisis’s impact on drug availability is stark. In provinces such as Sistan and Baluchestan, import restrictions have caused shortages of essential medications, particularly for diabetic patients and those undergoing dialysis. Patients report difficulty obtaining necessary drugs, often resorting to visiting multiple pharmacies or paying exorbitant prices. Adverse reactions to domestically produced medications have further complicated treatments.
Contributing Factors to the Crisis
The pharmaceutical sector’s challenges are rooted in several contributing factors:
- Substantial Debts: Rising costs and delayed payments have strained financial resources.
- Systemic Mismanagement: Inefficiencies and bureaucratic hurdles hinder effective operations.
- Foreign Currency Shortages: The government’s inability to provide adequate foreign currency for importing raw materials and essential drugs has further aggravated the situation.
As a result, approximately 200 types of common medicines and hospital drugs are currently scarce or unavailable. The removal of the 4,200 toman preferential exchange rate has intensified these issues, creating a 40 trillion toman liquidity shortage in the supply chain. Delayed payments from insurers and difficulties in foreign currency allocations have also adversely impacted drug manufacturers and pharmacies.
Infrastructure Challenges
Frequent power outages caused by aging infrastructure and natural gas shortages have significantly disrupted production and operations. Each outage can halt industrial activities for about 24 hours, compounding financial losses and operational challenges.
Without swift and decisive action, the crisis in Iran’s pharmaceutical industry will continue to deepen, threatening the health and well-being of millions.
